Valuation
- Market cap
- 31,308,000
- Revenue TTM
- $20,650,000
- Net income TTM
- $-5,080,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -24.60%
- Debt to equity
- 0.00
Trading
- Volume
- 15,300
- Avg volume
- 13,882
- Day's range
- $2.76 – $3.01
- Shares out
- 10,436,000
- Stochastic %K
- 66%
- Beta
- 1.13
- Analysts
- Strong Buy
- Price target
- $8.57
Company profile
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mix...
Show more
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 204 487 7412
- Website
- https://www.medicure.com
- Address
- 2-1250 Waverley Street, Winnipeg, Canada
Latest news
No headlines yet.
